Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMSNASDAQ:ARAVNYSE:CTSTNASDAQ:GALTNASDAQ:SBBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AARAVARAVIVE$0.04$0.04$0.04▼$2.46$2.95MN/AN/AN/ACTSTCannTrustC$0.64C$0.64C$0.38▼C$8.17C$90.27MN/AN/AN/AGALTGalectin Therapeutics$2.19+0.7%$1.61$0.73▼$3.90$138.29M0.7411,977 shs236,995 shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARAVARAVIVE0.00%0.00%0.00%0.00%0.00%CTSTCannTrust0.00%0.00%0.00%0.00%0.00%GALTGalectin Therapeutics-2.25%-13.55%+68.22%+69.53%-4.82%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AARAVARAVIVEN/AN/AN/AN/AN/AN/AN/AN/ACTSTCannTrustN/AN/AN/AN/AN/AN/AN/AN/AGALTGalectin Therapeutics1.8541 of 5 stars3.50.00.00.03.61.70.0SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/AARAVARAVIVE 0.00N/AN/AN/ACTSTCannTrust 0.00N/AN/AN/AGALTGalectin Therapeutics 3.00Buy$6.00176.50% UpsideSBBPStrongbridge Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ARAV, SBBP, CTST, GALT, and ADMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49ARAVARAVIVE$9.14M0.32N/AN/AN/A∞CTSTCannTrustC$35.22M2.56N/AN/AN/A∞GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ASBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/ACTSTCannTrust-C$10.46MN/A0.00∞N/AN/AN/AN/AN/AGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ALatest ARAV, SBBP, CTST, GALT, and ADMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AARAVARAVIVEN/AN/AN/AN/AN/ACTSTCannTrustN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17ARAVARAVIVEN/AN/AN/ACTSTCannTrustN/AN/AN/AGALTGalectin TherapeuticsN/A0.080.08SBBPStrongbridge Biopharma0.383.002.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%ARAVARAVIVE35.80%CTSTCannTrust0.03%GALTGalectin Therapeutics11.68%SBBPStrongbridge Biopharma52.03%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%ARAVARAVIVE60.40%CTSTCannTrustN/AGALTGalectin Therapeutics50.10%SBBPStrongbridge Biopharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableARAVARAVIVE2073.56 million29.13 millionNo DataCTSTCannTrust576141.49 millionN/AOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableARAV, SBBP, CTST, GALT, and ADMS HeadlinesRecent News About These CompaniesRising Investment in Patient Support Drives a Greater Biopharma Focus on MeasurementMarch 5, 2024 | fiercepharma.comFMatinas BioPharma Holdings Inc (MTNB)February 10, 2024 | investing.comLytix Biopharma As Share Price (LYTIX.OL)November 15, 2023 | lse.co.ukAmbrx Biopharma Inc AMAMNovember 4, 2023 | morningstar.comMBiopharma’s rapid transition to omnichannel marketingSeptember 11, 2023 | pharmaphorum.comPHILS Hillstream BioPharma, Inc.August 19, 2023 | seekingalpha.comABUS - Arbutus Biopharma CorporationJuly 1, 2023 | finance.yahoo.comThe Nominees for Best Biopharma CEO of 2015 Are...April 25, 2023 | thestreet.comDay One Biopharma Shares Rise 13% After Positive Topline Results for TovorafenibJanuary 11, 2023 | marketwatch.comBiopharma Soars to the Computational CloudsOctober 9, 2022 | genengnews.comGAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and PatientsSeptember 22, 2022 | markets.businessinsider.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...September 23, 2021 | apnews.comAStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.September 23, 2021 | finance.yahoo.comPress Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaSeptember 14, 2021 | sharecast.comSXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaSeptember 14, 2021 | stockhouse.comStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...September 9, 2021 | apnews.comALeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...August 31, 2021 | apnews.comASecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With XerisAugust 31, 2021 | tmcnet.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisAugust 31, 2021 | finance.yahoo.comStrongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen NextAugust 14, 2021 | marketingsentinel.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARAV, SBBP, CTST, GALT, and ADMS Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.ARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 07/2/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.CannTrust NYSE:CTSTCannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.Galectin Therapeutics NASDAQ:GALT$2.18 +0.02 (+0.69%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
